Development of Leprosy and Type 1 Leprosy Reactions after Treatment with Infliximab: A Report of 2 Cases | Zendy

David M. Scollard | Zendy; M. Patricia Joyce | Zendy; Thomas P. Gillis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Development of Leprosy and Type 1 Leprosy Reactions after Treatment with Infliximab: A Report of 2 Cases

Author(s) -

David M. Scollard,

M. Patricia Joyce,

Thomas P. Gillis

Publication year - 2006

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/505222

Subject(s) - infliximab , leprosy , medicine , discontinuation , monoclonal antibody , dermatology , tumor necrosis factor alpha , immunology , monoclonal , surgery , antibody

Humanized monoclonal antibodies to tumor necrosis factor- alpha are valuable for the treatment of rheumatologic conditions, but they have been associated with the development of serious infections. We report the first 2 cases of leprosy developing after treatment with infliximab. After discontinuation of infliximab, both patients developed type 1 ("reversal") leprosy reactions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research